<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339127</url>
  </required_header>
  <id_info>
    <org_study_id>NMDARE-HSE</org_study_id>
    <nct_id>NCT04339127</nct_id>
  </id_info>
  <brief_title>Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis</brief_title>
  <acronym>NMDARE-HSE</acronym>
  <official_title>Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an
      estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite
      a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20%
      and a considerable morbidity rate.

      One of the contributing factors of bad prognosis is the development of encephalitis mediated
      by autoantibodies, most often directed against NMDA receptors, in the weeks following viral
      encephalitis.

      The description of this pathology is recent, the pathophysiology of this process remains
      poorly understood, and the management of these patients is not yet codified.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution.</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Autoimmune Encephalitis</condition>
  <condition>Anti NMDA Receptor Encephalitis</condition>
  <condition>Herpetic Encephalitis</condition>
  <arm_group>
    <arm_group_label>Cohort NMDARE-HSE</arm_group_label>
    <description>Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Description and analysis</intervention_name>
    <description>Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.</description>
    <arm_group_label>Cohort NMDARE-HSE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        12 patients diagnosed between January 2014 and January 2020
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in
             the CSF

          -  After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF

          -  Without age limit

        Exclusion Criteria- No respect of inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Honnorat</last_name>
    <role>Study Director</role>
    <affiliation>National Reference Center of autoimmune encephalitis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Honnorat, PhD</last_name>
    <phone>04 72 35 78 06</phone>
    <email>jerome.honnorat@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Géraldine PICARD</last_name>
    <phone>0472355842</phone>
    <email>geraldine.picard@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospice Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500,</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEROME HONNORAT, PhD</last_name>
      <phone>04 72 35 78 06</phone>
      <email>jejerome.honnorat@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Herpes Simplex</mesh_term>
    <mesh_term>Anti-N-Methyl-D-Aspartate Receptor Encephalitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

